Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2-3 randomised trial. (2018)

First Author: Adams R
Attributed to:  MRC Clinical Trials Unit as the London Hub for Trials Methodology Research funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/s2468-1253(17)30394-1

PubMed Identifier: 29254887

Publication URI: http://europepmc.org/abstract/MED/29254887

Type: Journal Article/Review

Volume: 3

Parent Publication: The lancet. Gastroenterology & hepatology

Issue: 3